Overexpression of cathepsin D (CD),
INTRODUCTION
The cathepsin D (CD) gene, an estrogen-regulated gene in human breast cancer cells, encodes a ubiquitous lysosomal aspartyl protease that is initially synthesized as inactive procathepsin D. The proenzyme is subsequently converted by posttranslational cleavage to its enzymatically active form (1, 2) . In estrogen receptor (ER)-positive breast cancer cells, overexpression of procathepsin D has been correlated with lymphatic metastasis, relapse, and short disease survival in several retrospective clinical studies (3) (4) (5) . The precise role CD plays in metastasis is not well defined but may involve proteolytic activity and/or interaction with the mannose 6-phosphate/insulin-like growth factor receptor (6, 7) . In normal breast cells, after its synthesis, CD is transported into the lysosomal compartment. In tumor cells CD is secreted into the surrounding medium. This results in delivery of CD to the plasma membrane rather than to the lysosome. The secreted CD can disrupt the adhesive interactions holding tumor cells in place and may open a channel through the basement membrane and interstitial stroma, resulting in invasion and metastasis (8) (9) (10) .
Procathepsin D is constitutively expressed in ERnegative breast cancer cells but is greatly induced by estrogen and tamoxifen, a partial estrogen agonist, in ER-positive breast cancer cells (11, 12) . Transcription from the CD gene is initiated at five sites spanning 52 bp and mapping at Ϫ20, Ϫ44, Ϫ51, Ϫ60, and Ϫ72 bp from the first base of the initiation codon (13) . Of the five start sites, estrogen stimulates transcription only from the site located downstream of the TATA box at Ϫ20 (13) . Molecular analysis of the CD promoter has revealed a cluster of transcription factor-binding sites that include potential sites for the ER, activator protein 2, and Simian virus-40 protein-1 (SP1) (12) . Transient transfection experiments demonstrated that a maximal induction of transcription could be obtained with the proximal 356 bp of the CD promoter (12) . This observation was attributed to a cluster of three estro-gen-responsive element (ERE)-like half-palindromes located in the truncated promoter (12) . It has been suggested that the ER stabilizes the TATA-controlled preinitiation complex, and that estrogen induction of CD is mediated by interaction of the ER with a nonconsensus ERE that requires synergy with other elements located upstream and/or downstream of the central ERE (13, 14) . In particular, much attention has focused on potential interactions of the ER with the ubiquitous transcription factor SP1 (14) . Gel shift experiments with an oligonucleotide bearing a putative ER-SP1-like sequence (Ϫ199 to Ϫ165 of the CD promoter) suggest that both the ER and SP1 bind to this site (14) . However, other experiments have suggested that the major site of ER activity is a nonconsensus ERE, located at Ϫ261 in the CD promoter (12) . In addition, a fourth ERE half-palindrome is located in a site homologous to the adenovirus major late promoter element (CD Ϫ124/Ϫ104) (12) . Recent studies have shown that this short region of promoter (Ϫ119 to Ϫ10) is also responsive to estrogen stimulation (15) . These studies suggest that the role of the ER in regulating cathepsin gene expression is complex and may proceed via multiple EREs located within the proximal promoter (15) .
The ER is a member of the nuclear hormone receptor superfamily. These transcription factors share a similar structure, consisting of an amino-terminal region that modulates the transcriptional activity of the receptor, a central DNA-binding domain, and a carboxyl-terminal ligand-binding domain (16) (17) (18) . The binding of agonist to the receptor initiates a conformational change in the ligand-binding domain that enables recruitment of coactivators, which are thought to enhance receptor/basal transcription machinery interactions to efficiently activate transcription (19) (20) (21) (22) (23) (24) (25) . Of the steroid receptors, the glucocorticoid receptor (GR) is, perhaps, the most extensively studied with respect to transcriptional activation within chromatin (26) (27) (28) (29) . In particular, studies of the glucocorticoid stimulation of the mouse mammary tumor virus (MMTV) have demonstrated that the receptor performs multiple functions in activating the promoter (30) . Not only does the GR remodel chromatin to allow ubiquitous transcription factors, such as nuclear factor 1 (NF1), to establish a preinitiation complex, but it is also directly involved in the recruitment of the basal machinery to the promoter (31, 32) . Studies with the MMTV promoter help to establish the fundamental role of chromatin structure in the hormonal activation of transcription in vivo (23, 26) .
In the present study, we have used the human CD proximal promoter as a model system to investigate the mechanisms by which the ER stimulates transcription in MCF-7 cells. By analyzing transcription factor-DNA interactions on transiently transfected promoters, we observed estrogen-induced protein binding at the promoter in vivo. Subsequent in vitro DNA binding experiments confirmed that the estrogen-induced binding in vivo did not result from changes in expression of the protein. Southwestern and UV cross-linking studies with a short promoter probe, CD Ϫ124/Ϫ104, demonstrated that two proteins of 44 kDa and 43 kDa were bound specifically. Further experiments revealed that the proteins were upstream stimulatory factors 1 and 2, (USF-1 and USF-2). Point mutations within the USF-binding site in the CD promoter abolished USF binding and reduced the levels of both basal transcription and estrogen-stimulated transcription. These data suggest that USF-1 and USF-2 play important roles in mediating estrogen-inducible transcription of the CD gene in human breast cancer cells.
RESULTS

Estrogen Enhances CD Promoter Activity by the Recruitment of Transcription Factors
Within a small fragment of the proximal human CD promoter (Ϫ365 to Ϫ10) that is sufficient to mediate estrogen responsiveness, there are multiple potential transcription factor-binding sites (11, 12) . To dissect the mechanisms by which this promoter fragment allows estrogen regulation, we have used a MCF-7 cell line as a model system. In preliminary experiments we used RT-PCR to quantify estrogen activation of the endogenous CD promoter. Cells treated with 10 nM E 2 for 24 h exhibited a 6-fold increase in CD mRNA levels compared with untreated cells (Fig. 1A) . In contrast, within the same cells ␤ 2 -microglobulin mRNA levels were unaffected by E 2 treatment (Fig. 1A) . Analysis of a transiently introduced proximal human CD promoter/ CAT reporter plasmid into MCF-7 cells confirmed E 2 activation of the endogenous gene, with a 6-fold induction of chloramphenicol acetyltransferase (CAT) activity (Fig. 1B) . The E 2 induction was specific for the CD promoter as the CAT reporter plasmid without the promoter was unresponsive to E 2 (Fig. 1B) .
Transient transfections represent a powerful approach to characterize cis-regulatory sequences. More recently we have demonstrated that it is possible to use transient transfection assays to characterize proteins that mediate the transcriptional response (31) . To investigate the transcription factor loading on the CD promoter, we cotransfected MCF-7 cells with the CAT reporter and an ER expression vector. In vivo footprinting with Exonuclease III detected a single major estrogen-inducible stop indicative of a bound protein (Fig. 2B ). This 5Ј-boundary is consistent with a protein or proteins bound at or adjacent to the E box sequence within the CD promoter ( Fig. 2A) , a region protected by deoxyribonuclease I (DNase I) footprinting in vitro (12, 15) . Those experiments indicated that the E 2 -enhanced transcription from the CD promoter is consistent with the enhanced transcription factor loading on the promoter in vivo.
Identification of Nuclear Factors That Bind the E Box of the CD Promoter
To biochemically characterize E 2 -dependent protein binding, we synthesized oligonuleotides that encompassed sequences from Ϫ124 to Ϫ104 of the CD promoter (CD Ϫ124/Ϫ104). The CD Ϫ124/Ϫ104 sequence contains a GC island, a half-ERE (5Ј-GTACC), and an E box (5Ј-CACGTG) as potential transcription factor binding sites. These include transcription factors such as SP1, ER, and the basic helix-loop-helix (bHLH) transcription factors, c-myc, Myo D, USF-1, and USF-2 (33-38). Our gel mobility shift assays detected a single retarded protein-DNA complex with the nuclear extract from cells that were untreated or treated with E 2 (Fig. 3, compare lanes 1-3) . Interestingly, and in contrast to what was seen with the in vivo footprinting assay (Fig. 2B) , there was no significant increase in binding with extracts prepared from E 2 -treated cells compared with untreated cells (Fig. 3,  compare lanes 2 and 3) . This band appeared to be specific as it was completely competed away by the A, E 2 induction of endogenous CD mRNA accumulation. mRNA was isolated from MCF-7 cells untreated or treated with E 2 for 24 h. Twenty micrograms of total RNA were converted into cDNA with poly(dT) 12Ϫ18 . An aliquot of cDNA corresponding to 18 g total RNA was used in PCR reactions with CD-specific primers to generate a product of 178 bp in length. cDNA corresponding to 2 g total RNA was used with ␤-microglobulin specific primers as an internal control. PCR products were analyzed on a 5% polyacrylamide denaturing gel, followed by autoradiaography. Lane 1, Control cells; lane 2, cells treated with 10 nM E 2 . B, E 2 activation of transiently transfected CD promoter/CAT reporter gene. MCF-7 cells were transiently transfected with 10 g pCD/355 and 5 g HEO (human ER expression vector). After 24 h of transfection, the cells were stimulated with 10 nM E 2 for an additional 24 h. Cell lysates were prepared and analyzed for relative CAT activity. The results were the means Ϯ SE of three independent experiments.
Fig. 2. Estrogen-Dependent Transcription Factor Loading in Vivo
A, Schematic diagram of protein-binding sites within the proximal human CD promoter. Binding sites for proteins are labeled and given a distinctive fill, and the transcription start sites are indicated by arrowheads. In ER-positive breast cancer cells, estrogen only induces a TATA box-dependent transcription from Ϫ20. B, E 2 -induced transcription factor loading on the CD promoter in vivo. MCF-7 cells were transiently cotransfected with pCD/355 and HEO and treated or untreated with E 2 for 24 h before harvesting. Isolated nuclei were partially digested with HindIII and Exonuclease III to detect specific stops corresponding to 5Ј-boundaries of transcription factors bound to the CD promoter. After purification, each sample was analyzed using linear Taq polymerase amplification with a 32 P-labeled single-stranded primer specific for the bacterial CAT gene. Purified products were analyzed on a 5% polyacrylamide denaturing gel, followed by autoradiography. Lane 1, x 174 size marker; lanes 2 and 3, E 2 -treated and untreated sample, respectively. unlabeled CD Ϫ124/Ϫ104 probe, but not by the unlabeled SP1 DNA (Fig. 3 , compare lanes 3, 4, and 6). However, the CD Ϫ124/Ϫ104 binding was partially competed away by a 250-fold excess of an unlabeled consensus ERE probe (Fig. 3 , compare lanes 3, 4, and 5). Inspection of the two probes revealed that the ERE and CD Ϫ124/Ϫ104 share a sequence that is identical at 9 of 10 bases and may suggest that either ER and/or E box binding protein(s) bind to CD Ϫ124/Ϫ104 sequence in this electrophoretic mobility shift assay (EMSA) (Fig. 3) .
The protein-DNA complex detected in the EMSA may contain one or more proteins bound to the DNA probe. To characterize the nuclear protein(s) that bind the CD Ϫ124/Ϫ104 element, we turned to Southwestern blot analysis. The CD Ϫ124/Ϫ104 probe specifically detected two proteins with apparent molecular mass of ϳ43 kDa and 105 kDa in nuclear extract but not to a BSA control (Fig. 4 , compare lanes 1-3). In agreement with results seen with the gel mobility shift assay, there were no significant differences in the levels of nuclear proteins detected in extracts prepared from control and E 2 -treated cells (Fig. 4 , compare lanes 1 and 2). To directly compare the protein binding seen in the gel mobility shift assay and the Southwestern assays we performed UV cross-linking experiments. The advantage of the UV cross-linking assay is that it measures the DNA-protein interactions in solution under nondenaturing conditions. Consistent with the Southwestern experiments, we were able to crosslink the CD Ϫ124/Ϫ104 probe with polypeptides of 43 kDa and 44 kDa as well as diffuse protein(s) of ϳ105 kDa (Fig. 5 , compare lanes 1-7). As seen in the gel mobility shift assay, the interaction of the CD Ϫ124/ Ϫ104 probe with the 43-kDa and 44-kDa proteins was competed away completely by an excess of unlabeled CD Ϫ124/Ϫ104 probe and partially competed by an equivalent excess of unlabeled ERE probe ( Fig. 5 ., compare lanes 9 and 10). In addition, binding of the labeled probe to the 44-kDa and 43-kDa proteins was unaffected by 250-fold molar excess of unlabeled SP1 oligonucleotide (Fig. 5, lane 11) . In contrast, the binding of ϳ105 kDa protein(s) was not competed by a 250-fold molar excess of unlabeled CD Ϫ124/Ϫ104 probe, suggesting that the interactions with the CD Ϫ124/Ϫ104 probe might be nonspecific. Interestingly, the interaction of the CD Ϫ124/Ϫ104 probe with the ϳ105 kDa protein(s) was partially competed away by a 250-fold molar excess of unlabeled SP1 probe (Fig. 5,  lane 11) . Further, proteinase K digestion completely eliminated all DNA protein binding (Fig. 5 , compare lanes 2, 7, and 8). Taken together, the results indicated that the 44-kDa and 43-kDa proteins were responsible for the sequence-specific interaction with the CD Fig. 3 . Sequence-Specific Binding of Proteins to a CD Ϫ124/Ϫ104 Sequence EMSA was conducted using nuclear extracts (2 g) from MCF-7 cells with a 32 P-labeled CD Ϫ124/Ϫ104 probe. The binding reactions were analyzed on a 5% polyacrylamide nondenaturing gel, followed by autoradiography. Lane 1, Probe control without nuclear extract; lanes 2 and 3, probe with nuclear extract from E 2 -untreated cells and treated cells, respectively; lanes 4, 5, and 6, probe with nuclear extract from E 2 -treated cells, the reaction containing 250-fold molar excess unlabeled double-stranded DNA CD Ϫ124/Ϫ104 probe, ERE, and SP1 competitor, respectively. The sequences of the probes are given below the panel. An aliquot (40 g) of nuclear extract from MCF-7 cells was separated on a 7.5% SDS-PAGE gel. The protein was transferred to a nitrocellulose membrane and probed with 32 Plabeled CD Ϫ124/Ϫ104 probe, followed by autoradiography. Lane 1, Nuclear extract from E 2 -treated cells; lane 2, nuclear extract from E 2 -untreated cells; lane 3, BSA as a negative control.
Ϫ124/Ϫ104 DNA sequence seen in the biochemical assays (Figs. 3-5) .
The specific interactions of the 43-kDa and 44-kDa proteins with a fragment of the CD promoter that contains an E Box immediately suggested the bHLH transcription factors USF-1 and USF-2 as candidate proteins (39, 40) . To test this possibility, we compared a purified USF-1 protein with the nuclear extract by gel mobility shift assays (Fig. 6 ). The EMSA with purified USF-1 protein displayed a similar migration of the DNA-protein complex as in MCF-7 nuclear extracts (Fig. 6A, lanes 2 and 4) . We confirmed that the proteins in the nuclear extract bound to the CD Ϫ124/Ϫ104 probe were, in fact, USF-1 and USF-2 by gel supershift assays with anti-USF-1 and anti-USF-2 antibodies (Fig. 6B, lanes 2, 4, and 6 ). The DNA-nuclear factor complex was supershifted in the presence of either USF-1 or USF-2 antibodies but was unaffected by ER or GR antibodies (Fig. 6B, compare lanes 3-6) . This would be consistent with a USF-1/USF-2 heterodimer at the promoter, as both antibodies shift essentially the total DNA-protein complex (Fig. 6B, lanes 2, 4, and 6 ). Control experiments confirm that the interactions in the nuclear extracts include USF-1 and USF-2 by demonstrating that both antibodies shift the complex with extracts, but only the USF-1 antibody shifts the complex with purified USF-1 (Fig. 6B , compare lanes 4 and 6 with 8 and 9). These experiments are consistent with the idea of USF-1 and USF-2 as the E 2 -dependent factor(s) detected by in vivo footprinting (Fig. 2B ).
E Box-Mutated CD Promoter Activity and Transcription Factor Binding
Previous studies have found that an E box has the consensus sequence CANNTG and is the binding site for homo-or heterodimers of bHLH proteins (34, 41) . In the E box enhancer sequence (CACGTG), the cental C and G bases, shown in bold, are the most important nucleotides for USF binding (34) . Mutation of this core sequence will abolish USF binding in vitro (41) . To understand the contributions that the E box makes to E 2 regulation of CD transcription, we mutated the central C and G of the E box core to A and T (leaving the E box consensus sequence, CAatTG, intact) and used the mutated CD Ϫ124/Ϫ104 probe to test for USF binding. The CDmut Ϫ124/Ϫ104 probe was not bound by either recombinant USF-1 or nuclear proteins (Fig. 7A, compare  lanes 9-11) . In addition, the mutated probe failed to inhibit binding to the wild-type probe, even at 250 molar excess (Fig. 7A, compare lanes, 2, 4, 5, and 7) . These experiments strongly suggest that the proteins bound to the E-box in the CD promoter are USF-1/2.
To test the contribution of the USF-binding site to promoter activity in vivo, we incorporated the same mutations as the CD Ϫ124/Ϫ104 oligonucleotides into the CD promoter/CAT gene construct pCD/355 (15) . In vivo footprinting assays failed to detect the estrogeninduced USF binding to the mutated E box promoter template, while the E 2 treatment effectively stimulated USF loading on the wild-type promoter (Fig. 7B , compare lanes 6 and 9). Close inspection of the footprinting assays revealed the appearance of a second E 2 -enhanced transcription factor adjacent to the fourth half-ERE in the mutated CD promoter (Fig. 7B, compare lanes 6 and 7) . The identity of this protein is not known at present, and it does not appear to be significantly enhanced by E 2 at the corresponding site on the wild-type promoter. However, it may be related to the residual induction by E 2 seen in the absence of an intact E box. probe. An aliquot (2 g) of nuclear extract from MCF-7 cells or various amounts of purified recombinant USF-1 were used for the EMSA as described in Fig. 3 . Lane 1, Probe control without protein; lane 2, probe with the nuclear extract; lanes 3, 4, and 5: probes with 0.4, 4, and 40 ng of purified USF-1, respectively. B, USF binding to the CD Ϫ124/Ϫ104 sequence as a heterodimer in nuclear extracts. An aliquot (2 g) of nuclear extract from MCF-7 cells or purified USF-1 (4 ng) was used for a gel supershift assay using the same procedures as those in Fig. 3 , except another 20-min incubation was added after addition of antibodies (1 g). Lane 1, Probe with nuclear extract from E 2 -untreated cells; lane 2, probe with nuclear extract from E 2 -treated cells; lanes 3, 4, 5, and 6, probe with nuclear extract from E 2 -treated cells, the reaction containing rabbit polyclonal ER antibody, rabbit polyclonal USF-1 antibody, mouse monoclonal GR antibody, and rabbit polyclonal USF-2 antibody, respectively; lane 7, probe with purified USF-1; lanes 8 and 9, probe with purified USF-1, the reaction containing rabbit antibody against human USF-1, and rabbit antibody against mouse USF-2, respectively.
Fig. 7. Mutation of the Cathepsin D E Box Prevents USF-1 Binding in Vitro and in Vivo and Blocks Estrogen Activation of the Cathespin D Promoter
A, USF-1 fails to bind to the CDmut Ϫ124/Ϫ104 probe in vitro. An EMSA was performed as described in Fig. 3 . A competition experiment was conducted by adding a 250-fold molar excess of unlabeled probe to the binding reaction. Lane 1, CD Ϫ124/Ϫ104 probe; lane 2: CD Ϫ124/Ϫ104 probe with the purified USF-1; lanes 3 and 4: CD Ϫ124/Ϫ104 probe with the purified USF-1 and a 250-fold excess of unlabeled CD Ϫ124/Ϫ104 and CDmut Ϫ124/Ϫ104 probes, respectively; lane 5, CD Ϫ124/Ϫ104 probe with the nuclear extract; lanes 6, 7, and 8: CD Ϫ124/Ϫ104 probe with the nuclear extract and a 250-fold excess of unlabeled CD Ϫ124/Ϫ104, CDmut Ϫ124/Ϫ104 and SP1 probes, respectively; lane 9, CDmut Ϫ124/Ϫ104 probe; lanes 10 and 11, CDmut Ϫ124/Ϫ104 probe with the purified USF-1 and the nuclear extract, respectively. B, Disruption of USF binding to the mutated CD promoter in vivo. An in vivo footprinting assay was performed in transiently transfected MCF-7 cells as described in Fig. 2 , using a site-directed mutated construct (pMCD/355) as well as a wild-type construct (pCD/355). Lane 1, x 175 DNA size marker; lanes 2-5, four DNA sequence tracks with mutated template; lanes 6 and 7, mutated templates, the cells treated and untreated with E 2 , respectively; lanes 8 and 9, wild-type templates, the cells untreated and treated with E 2 , respectively; lanes 10-13, four DNA sequence tracks with wild-type template. C, E 2 activation is reduced with a mutated CD promoter. A CAT assay was carried out as described in Fig. 1B , using the wild-type construct pCD/355 and mutated construct pMCD/355 transfected into MCF-7 cells that were either untreated or treated with 10 nM E 2 .
To confirm a functional role for USF in E 2 induction of CD gene expression, MCF-7 cells were transiently transfected with either the wild-type or mutated CD-CAT reporter plasmids (Fig. 7C ). In agreement with the USF loading experiments, CAT assays demonstrated that the E 2 induction was reduced in pMCD/355 transfected cells by 90% relative to the wild-type construct (Fig. 7C) . Protein binding at the E box appeared to contribute both to the induced and basal levels of expression as the basal transcription from the mutated construct is reduced by 80% relative to the wild-type promoter (Fig. 7C) . Finally, while the E 2 response from the mutated promoter is significantly less than seen with the wild type, it does represent a 4-fold elevation over the reduced basal level of expression seen with the mutated promoter (Fig. 7C) . This E 2 induction may be related to the hormone-dependent protein binding downstream of the E box and serves to highlight the importance of the USF/E box interaction in providing a robust activation of the CD promoter in vivo.
DISCUSSION
CD is an important protease that is expressed in human breast cancer cells (1, 2) . Transcription from this gene occurs with multiple initiation start sites, one of which is stimulated with estradiol (13). This effect of E 2 is of particular interest as the ER status of breast tumors is an important prognostic indicator for the clinical outcome in breast cancer (3) (4) (5) . In our studies, we have begun to examine the mechanisms by which the ER activates the CD promoter. Our analyses demonstrate that the hormonal induction of the promoter seen in the endogenous gene is recapitulated with a minimal promoter element (Figs. 1 and 2) . Further, in vivo footprinting experiments revealed E 2 -dependent binding of a protein(s) at an E box (CACGTG) element within the proximal promoter (12, 42) (Fig. 2) . Subsequent biochemical experiments demonstrated that these proteins correspond to the ubiquitous transcription factors USF-1 and USF-2 (39, 40) (Figs. 3-6 ). The enhanced binding of USF-1/2 on the promoter occurs in the absence of detectable posttranslational modifications or changes in the levels of the ER or USF-1/2 (Figs. 4 and 5, and data not shown). The contribution that USF-1/2 binding makes to CD activation by the ER was demonstrated by experiments in which mutation of the E box prevented USF-1/2 binding both in vitro and in vivo (Fig. 7, A and B) . Incorporation of the same mutations into the promoter blocked ER-mediated activation of transcription in vivo. These experiments suggest a model for ER stimulation of the CD promoter in which recruitment of USF-1/2 to the promoter is required for activation of transcription.
The ER-mediated recruitment of USF-1/2 to the CD promoter is reminiscent of observations obtained with the MMTV system (26, 30) . In these studies the GR mediates the recruitment of NF1 and octamer transcription factors to the promoter to stimulate gene expression (31, 32) . These analyses have suggested the model for steroid hormone action whereby the GR initiates a cascade of events that leads to the remodeling of MMTV chromatin to allow access by ubiquitous nuclear proteins. As the chromatin structure of the CD gene promoter has not been described, it is not possible to draw a detailed comparison with the MMTV promoter. However, while these activation profiles are similar, there are distinct differences that can be examined. For example, the recruitment of NF1 and octamer transcription factor at the MMTV promoter, predicated upon the remodeling of MMTV chromatin, has not been observed when the promoter was transiently transfected into cells (32) . In contrast, the ERmediated loading of USF-1/2 to the CD promoter is hormone dependent on transient-transfected templates (Figs. 2B and 7B) . Indeed, the USF-1/2 recruitment is more reminiscent of hormone-dependent recruitment of the TATA binding protein on both stable and transient templates (31, 32) . Consequently, it would be of great interest to ascertain the chromatin structure of the CD promoter and to determine whether the ER-dependent binding of USF-1/2 is maintained on the chromatin copy of the gene.
The mutation of the E box in the context of the proximal promoter results in a diminution of the basal and ER-stimulated transcription (Fig. 7) . However, the mutated promoter retains a limited degree of responsiveness to E 2 that is mirrored by an enhanced hormone-stimulated binding of a protein(s) to the ERE half-site on the CD promoter containing a mutated USF site. Previous in vivo footprinting experiments had been interpreted as indicating that the major E 2 enhanced binding was attributed to the ER (15) . The mutation of the E box establishes that it a USF-1/2 complex that is the major protein entity on the promoter that forms as part of ER stimulation of transcription (Fig. 7B) . The identity of this protein with a boundary at Ϫ111 of the CD promoter is unknown at present. However, its interaction at or adjacent to the functional ERE half-site makes the ER a strong candidate (15) . The enhanced binding at this Ϫ111 site on the mutated promoter may result from a number of possibilities. First, it may simply result from the fact that the mutation, within the E box, by blocking the binding of USF-1/2, which is upstream of the new protein boundary, the exonuclease proceeds through until it encounters the bound protein(s). Alternatively, the failure of USF-1/2 to bind the mutated site may alleviate potential stearic considerations, thereby allowing for better binding at the site. Further in vitro footprinting experiments with purified USF and ER proteins will be necessary to allow us to decide between these possibilities.
Alternatively, the fact that the promoter exhibits a diminished but consistent E 2 response, when the USF-1/2 site is mutated, may reflect the contributions of more distal estrogen-responsive regions of the promoter described earlier (12) . These include nonconsensus EREs at Ϫ362, Ϫ261, Ϫ199, and Ϫ87 of the promoter as defined by gel shift and transient transfection assays (12, 14) . Indeed the site at Ϫ261 was shown to require sequences that include the sequences defined by our studies for full function (12) . Interestingly our in vivo footprinting assays do not detect protein-DNA interactions at these sites, which makes a direct comparison with our studies of the Ϫ124 region more difficult (see below).
Previous experiments demonstrated a synergistic interaction between the ER and SP1 at the heat shock protein 27 and CD promoters (14, 43) . For the CD promoter these studies have focused on an ERE halfsite (Ϫ199 to Ϫ165) that is distal to the region of the promoter examined here (Ϫ124 to Ϫ104). Biochemical and transfection evidence suggest that there is a functional interaction of the ER with SP1 that mediates the estrogen response (14) . In the CD promoter there are potential SP1-and ER-binding sites adjacent to the E box ( Fig. 2A) (15) . Our biochemical assays find no evidence for interaction of the ER with USF-1/2 on the E box (Figs. 3-6 ). The results with respect to SP1 are a bit more complicated. In EMSA competition experiments and antibody supershift studies with anti-SP1, we find no evidence for SP1 interacting with this short region (Ϫ124 to Ϫ104) of the CD promoter (W. Xing and T. K. Archer, data not shown). However, both Southwestern blotting and UV cross-linking experiments leave open the possibility of an interaction. Southwestern blotting detects a protein of approximately 105 kDa, and in UV cross-linking experiments an unlabeled SP1 probe competes this band away without affecting the labeled USF-1/2 probe interactions with USF-1 and USF-2. Thus, one interpretation is that this putative SP1 site is a relatively weak site such that interactions are not stable to gel shift conditions but are maintained under the liquid-solid phase interaction obtained with Southwestern blotting experiments or stabilized by UV cross-linking.
The ability to detect proteins on transiently transfected templates provides an important tool for ascertaining those proteins that interact with a promoter from potential binding sites identified through computer-based analysis of the sequences (44, 45) . Indeed, our experiments suggest that the presence of a number of binding sites, as indicated on the CD promoter, does not necessarily mean that these sites, and the proteins that can potentially bind to them, play a significant role in activation of transcription. In the future, it will be important to determine the precise role or potential role of SP1-USF-1/2 interactions on this promoter. Similarly, while the binding of USF-1/2 at the promoter is hormone dependent, the precise mechanism by which this occurs in the absence of identifiable changes in USF-1/2 levels is not known. Thus, it will be important to determine whether the recruitment of USF-1/2 results from direct or indirect interactions with the ER and the mechanism(s) by which this results in the formation of an active preinitiation complex on the CD promoter in vivo.
MATERIALS AND METHODS
Oligonucleotides
The following oligonucleotides were synthesized on an Applied Biosystems (Foster City, CA) DNA synthesizer 321.
CAT 5Ј-GCT CCT GAA AAT CTC GCC AAG 5CD: 5Ј-GCT GCA CAA GTT CAC GTC CAT 3CD: 5Ј-TGC CAA TCT CCC CGT AGT ACT G 5␤M: 5Ј-ACC CCC ACT GAA AAA GAT GA 3␤M: 5Ј-ATC TTC AAA CCT CCA TGA TG 5CDmut: 5Ј-CCG GCC GCG CCC Aat TGA CCG GTC CGG G-3Ј 3CDmut: 5Ј-C CCG GAC CGG TCA atT GGG CGC GGC CGG-3Ј ERE: 5Ј-CAA AGT CAG GTC ACA GTG AGG TGA TCA AAG A 3Ј-GTT TCA GTC CAG TGT CAC TGG ACT AGT TTC T Sp1: 5Ј-GAT GCG GTC CCG CCC TCA GC-3Ј 3Ј-CTA CGC CAG GGC GGG AGT CG-5Ј CD Ϫ124/Ϫ104: 5Ј-GGC CGC GCC CAC GTG ACC GGT 3Ј-CCG GCG CGG GTG CAC TGG CCA CDmut Ϫ124/Ϫ104: 5Ј-GGC CGC GCC CAatTG ACC GGT CC-3Ј 3Ј-CCG GCG CGG GTtaAC TGG CCA GG-5Ј
Plasmids and Bacterial Strains
Plasmids pCD/355, proximal CD promoter from Ϫ365 to Ϫ10, and HEO, human ER expression vector, were kindly provided by Dr. S. Safe (Texas A & M University, College Station, TX). Escherichia coli strain DH5␣ was used for routine transformation experiments. Plasmid preparations for transfection were by alkaline lysis followed by cesium chloride gradient centrifugation (46) .
Cell Line and Cell Culture
Human breast cancer cells (MCF-7) were routinely maintained in a humidified 37 C incubator with 5% CO 2 and cultured in Modified Eagle Medium (MEM) containing 10% FBS (GIBCO BRL, Gaithersburg, MD), 2 mM L-glutamine, 100 U/ml penicillin, and 100 g/ml steptomycin.
mRNA Isolation and RT-PCR
mRNA was isolated with Trizol reagent (GIBCO BRL) according to the manufacturer's instructions. Twenty micrograms of total RNA were annealed to 750 ng of poly (T) 12Ϫ18 at 65 C for 5 min, after which the first-strand cDNAs were synthesized using a first-strand cDNA synthesis kit (Pharmacia Biotech, Piscataway, NJ). After a 10-min incubation at 75 C, an aliquot (90%) of total synthesized first-strand cDNAs was amplified using 32 P-labeled primers (5CD and 3CD) by PCR, and the remainder (10%) was amplified utilizing 32 P-labeled human ␤ 2 -microglobulin primers (5␤M and 3 ␤M) as an internal standard. The RT-PCR products were resolved on a 8% polyacrylamide denaturing gel and visualized by autoradiography.
Transient Transfections
MCF-7 cells were seeded into 150-mm tissue culture plates (10 6 cells per plate) in phenol red-free MEM plus 5% double dextran charcoal-stripped FBS. The following day, medium was removed and replaced with fresh estrogen-free medium. Transient transfections were carried out with 10 g of pCD/ 355 or pMCD/355 and 5 g of HEO for 18 h, using calcium phosphate coprecipitation (31) . The following day, fresh media, with or without 10 nM estradiol (E 2 , Sigma Chemical Co., St. Louis, MO), was added for an additional 24 h before harvesting.
Chloramphenicol Acetyltransferase (CAT) Assay
CAT assays were performed as described previously (47) . 
In Vivo Exonuclease III Footprinting Assays
MCF-7 cells were transfected as described above, and nuclei were isolated and partially digested with HindIII and exonuclease III to detect the 5Ј-boundaries of transcription factors bound to the CD promoter as described previously (44) . After purification, DNA was completely digested with HindIII to provide an internal standard, and 10 g of each sample were analyzed using linear Taq polymerase amplification with a 32 P-labeled oligonucleotide (32) . Purified extended products, together with DNA sequencing tracks, were analyzed on a 5% polyacrylamide denaturing gel and visualized by autoradiography.
Preparation of Nuclear Extracts
Nuclear extracts were prepared as described previously (48) . MCF-7 cells were washed in PBS and lysed on ice for 5 min in Buffer E [0.3% Nonidet P-40 (NP-40), 10 mM Tris-HCl (pH 8.0), 60 mM NaCl, 1 mM EDTA, 1 mM dithiothreitol (DTT), 1 mM phenylmethylsulfonylfluoride]. Nuclei were pelleted by spinning for 5 min at 2500 rpm at 4 C. The pellet was washed in an Buffer E lacking NP-40 and resuspended in 100 l of Buffer C (20 mM HEPES, pH 7.9, 0.75 mM spermidine, 0.15 mM spermine, 0.2 mM EDTA, 2 mM EGTA, 2 mM DTT, 20% glycerol, 1 mM phenylmethylsulfonylfluoride). NaCl was added to a final concentration of 0.4 M, and the nuclei were gently shaken for 20 min at 4 C, and then spun for 10 min at 12,000 rpm at 4 C. Nuclear extracts were stored at Ϫ80 C.
EMSA
EMSAs were as described previously (49) . Briefly, doublestrand oligonucleotides (ERE, SP1, CD Ϫ124/Ϫ104, and CDmut Ϫ124/Ϫ104) were labeled at the 5Ј-end using T4 polynucleotide kinase and [␥-32 P] ATP. Nuclear extracts from MCF-7 cells treated or untreated with 10 nM E 2 for 24 h or purified recombinant USF-1 protein (kindly provided by D. Steger and J. Workman, Pennsylvania State University, University Park, PA), were incubated in a binding buffer containing 10 mM Tris-HCl (pH 7.5), 50 mM NaCl, 3 mM DTT, 10% glycerol, 0.05% NP-40, 0.1 mM ZnCl 2 , 50 g/ml poly(deoxyinosinic-deoxycytidylic)acid, and 0.02 pmol of labeled DNA probe. After addition of radiolabeled probe, the mixture was incubated at room temperature for another 15 min. Excess unlabeled DNA competitor was added 5 min before the addition of radiolabeled DNA probe. The reaction mixture was analyzed using a 5% nondenaturing polyacrylamide gel in 1 ϫ Tris-borate-EDTA buffer. For the gel supershift assay, 1 g of antibody was added into the reaction mixture and incubated at room temperature for an additional 15 min. Gels were dried and were visualized by autoradiography.
Southwestern Analysis
The Southwesten analyses were performed as described previously (50) . Briefly, 50 g nuclear extracts were loaded onto a SDS-PAGE denaturing gel, and electrophoresis was carried out at 15 mA for 5 h. Proteins were then transferred to Hybond-ECL nitrocellulose (Amersham, Arlington Heights, IL) and membranes were incubated, at room temperature for 60 min, in a buffer containing 5% dry skim milk, 25 mM NaCl, 5 mM MgCl 2 , 25 mM HEPES (pH 7.9), and 0.5 mM DTT. The binding reaction was performed in the same buffer with 10 6 cpm/ml of 32 P-labeled CD Ϫ124/Ϫ104 probe, in the presence of 5 g/ml of salmon sperm DNA, at room temperature for 18 h. Before autoradiography, blots were washed four times at room temperature utilizing the same buffer.
UV Cross-Linking
The UV cross-linking protocol was carried out as described previously (51) . Protein DNA binding was at room temperature for 20 min with 5 g nuclear extract in EMSA binding buffer. The vials were then sealed, and a GS Gene Linker (Bio-Rad Laboratories, Richmond, CA), set at 125 mJ, was used for cross-linking. Subsequently, samples were electrophoresed as described above, and then the gel was dried before autoradiography.
Site-Directed Mutagenesis
Mutagenesis was performed using the QuikChange SiteDirected Mutagenesis Kit (Stratagene, La Jolla, CA). In brief, a supercoiled, double-stranded pCD/355 plasmid DNA with the proximal CD promoter (Ϫ365 to Ϫ10) was used as a template. The two synthetic oligonucleotides of 5CDmut and 3CDmut containing a mutated E box (CAatTG) were extended during the temperature cycling by means of Pfu DNA polymerase. The extension product was treated with 10 U of DpnI endonuclease at 37 C for 1 h to digest the parental supercoiled double-stranded DNA template. The nicked vector DNA incorporating a mutated E box was then transformed into Epicurian coli XL1-Blue Supercompetent Cells. Individual clones were isolated, and the DNA was purified and sequenced to confirm which clones had the correct mutational changes.
DNA Sequence Analysis
The procedures were performed according to instructions provided by the manufacturer (Pharmacia Biotech). In brief, 4 g of double-stranded plasmid DNA were denatured with 0.4 M sodium hydroxide for 10 min, neutralized with 0.45 M sodium acetate, and precipitated in 70% ethanol. The purified DNA templates were annealed to the CAT oligo and sequenced using the dideoxy chain termination method with [␣-
35 S ]dATP. Chain elongation-termination reaction products were resolved on a 7% polyacrylamide denaturing gel. The gel was dried before autoradiography at room temperature with Kodak X-OMAT AR 5 film (Eastman Kodak, Rochester, NY).
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